The invisible wounds caused by post-traumatic stress disorder can dramatically affect mental health and diminish quality of life. According to the Sidran Institute, a nonprofit organization serving people who have experienced or witnessed traumatic events, PTSD is associated with an extremely high rate of medical and mental health service use. Patients may incur the highest per-capita cost of any psychological condition. It’s clear that more research must be conducted, and treatments developed, to address this unmet medical need. While there are currently more than 350 ongoing clinical research studies in PTSD, most are in the academic arena. Consequently, there is limited knowledge within industry on conducting these clinical trials. Having worked in PTSD research for several years, Premier Research understands the combination of expertise and nuance to achieve a successful clinical trial.
- Where Expertise Meets Nuance: Conducting PTSD Clinical Trials: Webcast
- Tuesday, April 24, 2018
- 11:00AM EDT | 4:00PM GMT | 5:00PM CST
- 1 hour
- Study design considerations, including assessment frequency and target population (military versus civilian).
- An overview of the CAPS-5 assessment, including the importance of the structured interview and alignment of the scoring rules.
- Recruitment strategies and site dynamics unique to this indication.
Senior Vice President, Clinical Development Services & Global Head of Neurosciences
Krista Armstrong has held leadership roles for Project Management and Operations delivery at Premier Research and now oversees the Neuroscience Business Unit. This Business Unit includes Premier’s most experienced Neuroscience clinical research professionals for psychiatric and neurological indications to ensure that the Premier team provides sponsors with the best possible regulatory and scientific, medical and operational delivery advice. Dr. Armstrong’s primary therapeutic and operational expertise has had a specific emphasis on psychiatric indications such as ADHD, schizophrenia, mood disorders, ASD, eating disorders, substance use disorders and PTSD as well as neurological conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy and stroke.
Dr. Armstrong’s clinical research experience spans more than 20 years in both academia and the pharmaceutical industry. At Premier Research, she led the integration of six acquisitions and grew the clinical operations department from 60 to more than 500 employees globally.
Dr. Armstrong received her doctorate in neuroscience from the University of Florida.
Frank W. Weathers
Professor, Auburn University, Department of Psychology
Dr. Weathers received his B.A. in Psychology from Butler University in 1984 and his Ph.D. in Clinical Psychology from Indiana University in 1990. He completed an internship at the Boston VA Medical Center, then served as a clinical research psychologist at the National Center for PTSD at the Boston VA until joining the Auburn faculty in 1997. His research interests include assessment and treatment of post-traumatic stress disorder, diagnosis and classification of psychopathology, and social information processing in anxiety, depression, and personality disorders. He has co-authored several widely used assessment measures in the field of traumatic stress, including the Clinician-Administered PTSD Scale and the PTSD Checklist. His teaching interests include assessment, psychological trauma, psychopathology, and cognitive-behavioral and interpersonal approaches to psychotherapy.